Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: A review

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 653-666

  Al Shakarchi, Israa ^a   Gullick, Nicola J ^a   Scott, David L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

IL 6; Review; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

ACUTE PYELONEPHRITIS; AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL ARTHRITIS; CELLULITIS; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INFECTION; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NAUSEA; NEUTROPENIA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STOMATITIS; SYSTEMATIC REVIEW (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS;

EID: 84880094171     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S41433     Document Type: Review

References (51)

1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007;120(11):936-939.
2. Al-Shakarchi I. Fragility Fractures in Rheumatoid Arthritis-A systematic review of the literature. Proceedings of the British Society of Rheumatology Conference; April 21-23, 2010; Birmingham, UK.
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies of rheumatoid arthritis. Lancet. 2007;370(9602):1861-1874.
4. Nishimoto N, Yoshiazaki K, Maeda K, etal. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30(7):1426-1435.
5. Navarro-Millán I, Singh J, Curtis JR. Systematic review of Tocilizumab for rheumatoid arthritis: A new biologic agent targeting the Interleukin-6 receptor. Clin Ther. 2012;34(4):788-802. e3.
6. Hashizume M, Mihara M. The roles of Interleukin-6in the Pathogenesis of Rheumatoid Arthritis. Arthritis. 2011;2011.
7. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609-632.
8. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937):356-361.
9. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm. 2006;63(24):2451-2465.
10. Genovese MC, McKay JD, Nasonov EL, etal. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The Tocilizumab in combination with traditional disease modifying anti-rheumatic drug therapy study. Arthritis Rheum. 2008;58(10): 2968-2980.
11. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350(21):2167-2179.
12. Hushaw LL, Sawaqued R, Sweis G, etal. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2010;6:143-152.
13. Feldmann M, Maini RN. Anti-TNF α therapy of rheumatoid arthritis; what have we learnt? Ann Rev Immunol. 2001;19:163-196.
14. Maini RN, Taylor PC, Szechinsji J, etal; CHARISMA Study Group. Double-blind randomized Controlled clinical trial of the interleukin-6 receptor antagonist, Tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829.
15. Hetland ML, Christensen IJ, Tarp U, etal; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide DANIBO registry. Arthritis Rheum. 2010;62(1):22-32.
16. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008;181:151-160.
17. Singh JA, Beg S, Lopez-Olivo MA. tocilizumab for rheumatoid arthritis: a cochrane systematic review. J Rheumatol. 2011;38(1):10-20.
18. Dayer J, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology. 2010;49(1):15-24.
19. Hirano T, Yasukawa K, Harada H, etal. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73-76.
20. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Ann Rev Immunol. 2005;23:1-21.
21. Mima T, Nishimoto N. Clinical value of blocking Il-6 receptor. Curr Opin Rheumatol. 2009;21(3):224-230.
22. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J Autoimmun. 1992;5 Suppl A:123-132.
23. Choy EH, Isenberg DA, Garrod T, etal. Therapeutic benefit of blocking Interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12): 3143-3150.
24. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538-542.
25. Hirano T, Matsuda T, Turner M, etal. Excessive production of interleukin 6/B cell stimulatory factor-2in rheumatoid arthritis. Eur J Immunol. 1988;18(11):1797-1801.
26. Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2008;2(1):75-82.
27. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-236.
28. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3-4):249-284.
29. Ward LD, Howlett GJ, Discolo G, etal. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6 receptor and gp-130. J Biol Chem. 1994;269(37): 23286-23289.
30. Lally F, Smith E, Filer A, etal. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005;52(11):3460-3409.
31. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992;19(1):22-25.
32. Kotake S, Sato K, Kim KJ, etal. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluid from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11(1):88-95.
33. Nakahara H, Song J, Sugimoto M, etal. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor (VEGF) production in rheumatoid arthritis. Arthritis Rheum. 2003;48(6):1521-1529.
34. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87(4):483-487.
35. Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). NICE technology appraisal guidance 247 [webpage on the Internet]. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://guidance.nice.org.uk/TA198. Accessed Sep 12, 2012.
36. Felson DT, Anderson JJ, Boers M, etal. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
37. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845-1850.
38. van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916-920.
39. Nishimoto N, Yoshizaki K, Miyasaka N, etal. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody-a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761-1769.
40. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-1584.
41. Jones G, Sebba A, Gu J, etal. Comparison of tocilizumab monotherapy versus monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
42. Nishimoto N, Miyasaka N, Yamamoto K, etal. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-19.
43. Smolen JS, Beaulieu A, Rubbert-Roth A, etal; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371(9617):987-997.
44. Emery P, Keystone E, Tony HP, etal. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-1523.
45. Nishimoto N, Hashimoto J, Miyasaka N, etal. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-1167.
46. Kremer JM, Blanco R, Brzosko M, etal. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to Methotrexate-results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3): 609-621.
47. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552-562.
48. Puolakka K, Blåfield H, Kauppi M, etal. Cost-effectiveness modeling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open Rheumatol J. 2012;6: 38-43.
49. Schoels M, Wong J, Scott DL, etal. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):995-1003.
50. Diamantopoulos A, Benucci M, Capri S, etal. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576-585.
51. Dougados M, Kissel K, Sheeran T, etal. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43-50.